Back to Search
Start Over
Nirmatrelvir/ritonavir treatment of patients with COVID-19 taking tacrolimus: case series describing the results of drug–drug interactions
- Source :
- Journal of International Medical Research, Vol 52 (2024)
- Publication Year :
- 2024
- Publisher :
- SAGE Publishing, 2024.
-
Abstract
- Nirmatrelvir/ritonavir is a novel drug combination that is authorized by the Food and Drug Administration for the treatment of coronavirus disease 2019 (COVID-19). Ritonavir is a cytochrome P450 3A inhibitor and a P-glycoprotein inhibitor that increases the plasma concentration of tacrolimus and other medications. We describe the cases of two patients treated with nirmatrelvir/ritonavir: a patient who had undergone kidney transplantation and another with a history of hematopoietic stem cell transplantation. Toxic concentrations of tacrolimus were induced in both. This case series highlights the risk associated with the concomitant administration of tacrolimus and nirmatrelvir/ritonavir.
- Subjects :
- Medicine (General)
R5-920
Subjects
Details
- Language :
- English
- ISSN :
- 14732300 and 03000605
- Volume :
- 52
- Database :
- Directory of Open Access Journals
- Journal :
- Journal of International Medical Research
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.7ced5cad2f114a42af8893d3c61d3fed
- Document Type :
- article
- Full Text :
- https://doi.org/10.1177/03000605241247705